Alginate biomaterials for the treatment of hepatic disorders
US-2016317570-A1 · Nov 3, 2016 · US
US9616088B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9616088-B2 |
| Application number | US-201414208820-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2014 |
| Priority date | Mar 13, 2013 |
| Publication date | Apr 11, 2017 |
| Grant date | Apr 11, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism.
Opening claim text (preview).
What is claimed is: 1. A putty, comprising: a hemostatic biopolymer comprising hydrophobically modified chitosan, polyvinyl alcohol as a secondary polymer, a borate salt ionic crosslinker, and a solvent. 2. The putty of claim 1 , wherein the hydrophobically modified chitosan comprises hydrophobic substituents covalently attached to the biopolymer. 3. The putty of claim 2 , wherein the hydrophobic substituents comprise from eight to eighteen carbon atoms. 4. The putty of claim 3 , wherein the hydrophobic modification is of 1 to 100 moles of hydrophobic substituent per 1 mole of biopolymer. 5. The putty of claim 1 , wherein the hydrophobically modified chitosan is selected from the group consisting of chitosan lactate, chitosan salicylate, chitosan pyrrolidone carboxylate, chitosan itaconate, chitosan niacinate, chitosan formate, chitosan acetate, chitosan gallate, chitosan glutamate, chitosan maleate, chitosan aspartate, chitosan glycolate and quaternary amine substituted chitosan and salts thereof. 6. The putty of claim 1 , wherein the polyvinyl alcohol is present in a concentration of between 5 wt % and 15 wt %. 7. The putty of claim 1 , wherein the polyvinyl alcohol has a molecular weight in of between 50,000 Da and 300,000 Da. 8. The putty of claim 1 , wherein the polyvinyl alcohol has a molecular weight in of between 125,000 Da and 140,000 Da. 9. The putty of claim 1 , wherein the polyvinyl alcohol is hydrolyzed in a range of 70% to 100%. 10. The putty of claim 1 , wherein the crosslinker is present in a concentration of between 0.1 wt % and 1.0 wt %. 11. The putty of claim 1 , wherein the borate salt is selected from the group consisting of sodium tetraborate decahydrate, sodium peroborate, and sodium metaborate. 12. The putty of claim 1 , wherein the hydrophobically modified chitosan is present in a concentration of between 0.1 wt % and 3.0 wt %. 13. The putty of claim 1 capable of providing a compressing force of between 5 and 15 N, 15 and 30 N, or 0.1 and 5N. 14. The putty of claim 1 , further comprising a water soluble reagent. 15. The putty of claim 1 , further comprising a water soluble reagent selected from the group consisting of human thrombin, bovine thrombin, recombinant thrombin, and human fibrinogen. 16. The putty of claim 1 , further comprising a reagent selected from the group consisting of fibrinogen, factor VIIa, Factor XIII. 17. The putty of claim 1 , further comprising a reagent that prevent microbial infections. 18. The putty of claim 1 , further comprising a reagent selected from the group consisting of an anti-microbial and an antibiotic. 19. The putty of claim 1 , further comprising a reagent selected from the group consisting of ampicillin, and penicillin. 20. The putty of claim 1 , further comprising a reagent selected from the group consisting of norfolxacin and silver.
Chitin, chitosan · CPC title
Celluloses · CPC title
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title
Alginic acid · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.